BioTie Therapies Chooses Tripos as Strategic Chemistry Partner in Drug Discovery
Tripos, Inc., a leading provider of drug discovery chemistry and informatics products and services, and BioTie Therapies Corp., a Finnish biotech company, have announced a partnership to enhance BioTie’s drug discovery efforts, which include innovative medicines for the treatment of dependence disorders, inflammatory diseases and thrombosis.
Under the agreement, Tripos will identify and optimize backup series for one of BioTie’s key drug discovery programs. Tripos’ LeadHopping(TM) technology is essential to identifying structurally distinct, though shape-similar, compounds whose chemistry is unrelated to that of the original lead and therefore free of patent restrictions. Tripos will then rapidly create compound libraries for in-house screening by BioTie.
Financial terms of the multiyear agreement were not disclosed.
“Tripos demonstrated its outstanding computational drug design capabilities in a pilot project, and we were impressed with its ability to quickly transform virtual chemistry into viable, high-quality screening. Those capabilities drove our selection of Tripos as our chemistry partner to accelerate BioTie’s drug discovery timelines,” said Jari Saarinen, BioTie president and CEO.
About Tripos, Inc.
Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Tripos collaborates with clients to accelerate and improve the creation of life-enhancing products. Within Tripos’ Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos’ Discovery Research (DR) business, Tripos’ medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at www.tripos.com .
About BioTie Therapies Corp.
BioTie Therapies Corp. (HEX:BTH1V) is a public Finnish biotech company specializing in pharmaceutical product development. Its main focus is on products for the treatment of dependence disorders, inflammatory diseases and thrombosis. For more information, please visit www.biotie.com .
This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as “expects,” “anticipates,” “projects,” “estimates,” “intends,” “plans,” “believes,” variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. We have identified certain factors that could cause actual results to differ materially from the forward-looking statements in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.
Tripos and the Tripos logo are registered trademarks of Tripos, Inc., and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners.
